Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Pharmacy First service: Why are people hesitant to visit a pharmacy for UTIs and shingles?

Pharmacy First service: Why are people hesitant to visit a pharmacy for UTIs and shingles?

Policy makers and healthcare leaders acknowledge that there’s hesitancy and the mindset of ‘GP first, not Pharmacy First’ among members of the public

With the Pharmacy First services scheduled for launch end of this month, legislators explored the potential of community pharmacies to offer specific diagnostic and treatment services in the second public evidence session of pharmacy inquiry this week (January 16).


The new service, which will enable pharmacists to offer advice and prescribe treatment for seven minor ailments, is expected to alleviate the pressure on the NHS, reduce GP workload, and cut waiting lists.

But MPs and healthcare leaders also acknowledged that there’s hesitancy and the mindset of ‘GP first, not Pharmacy First’ among members of the public.

“We must accept that many patients are used to seeing their GP as their first port of call for many health conditions. Pharmacy First is welcome, but there are going to be some restrictions on how quickly some patients will want to take up some of those services, rather than seeing their GP,” said William Pett, Head of Policy, Public Affairs and Research, Healthwatch England.

What is that hesitancy built around? Health and Social Care Committee Chair Steve Brine MP asked Pett.

Pett cited a Healthwatch England survey conducted in November 2023, which found that while the public were generally positive about going to pharmacy for things like sore throats and earache, the likelihood of patients going to pharmacies for UTIs and shingles was far less.

“One of the top reasons why people were unlikely to go to pharmacy for those two conditions was that they just prefer seeing their GP,” he told the committee.

There’s also lack of awareness about services offered in pharmacies, and privacy is another factor for people’s hesitancy to visit a pharmacy, especially on sensitive issues like UTIs.

“Many patients are not aware that pharmacy offers private consultation rooms, or do not have much faith in the privacy that those consultation rooms offer,” Pett explained.

Another reason is that patients think that they will be referred back to their general practice, if it is a more serious condition, and that could be a real frustration for a lot of patients.

Pett emphasised the need to build confidence among the public that they will be treated for that condition without being referred back to their GP.

Deborah Evans, Clinic Director and Superintendent Pharmacist, Remedi Health, opined that the biggest issue for the sector to deliver the Pharmacy First service will be around capacity.

She reminded the committee about the closures that have happened in community pharmacy due to which those that are still operating are having to do more.

“They are doing more with less, because of the funding model, which is not sufficient to support the sector.

“There is an issue around capacity and around capability, giving pharmacists the time and space to be able to develop,” she said.

 

 

More For You

Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less
NHS to invest millions to boost enhanced treatment for sickle cell patients

Approximately 17,000 people live in England with sickle cell disease

Pic credit: istock

NHS to invest millions to boost enhanced treatment for sickle cell patients

The Department of Health and Social Care has announced that it will invest £9 million towards the treatment of sickle cell patients.

Approximately 17,000 people live in England with sickle cell disease. Nearly 250 new cases of this inherited blood disorder is reported annually.

Keep ReadingShow less
NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients

An estimated 6,000 cases of multiple myeloma is diagnosed in the UK each year.

Pic credit: istock

NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients


NHS England has become the first in the world to introduce a ‘trojan horse’ therapy for the victims of blood cancer with the ground-breaking treatment slowing down the illness three-times more than existing treatments.

Keep ReadingShow less
Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less